Skip to main content

Blood Glucose Monitoring Devices Market to Worth USD 23.15 Billion by 2030 | Skyquest Technology

Blood glucose monitoring devices market is segmented based on the product, testing site, patient care setting, modality, application, and distribution channel. Based on the product, the market is bifurcated into self-monitoring and continuous blood glucose monitoring devices. Based on the testing site, the market is segmented into fingertip testing and alternate site testing. According to the patient care setting, it is segmented into self/home care and hospital & clinics. Based on modality, the market is bifurcated into wearables and non-wearables. According to the distribution channel, it is categorized into retail sales and institutional sales. Based on application, it is segmented into type 2 diabetes, type 1 diabetes and gestational diabetes- Industry Forecast 2023-2030

Westford, USA, July 14, 2023 (GLOBE NEWSWIRE) — According to SkyQuest, the increased incidence of diabetes can be attributed to several factors, including rapid urbanization and the growing prevalence of sedentary lifestyles in blood glucose monitoring devices market. As societies become more urbanized, there is a shift towards less physically active lifestyles and increased reliance on technology, leading to reduced physical activity levels and a higher risk of developing diabetes.

Browse in-depth TOC on the “Blood Glucose Monitoring Devices Market”            

  • Pages – 242
  • Tables –  166
  • Figures – 79

Get sample copy of this report:

https://www.skyquestt.com/sample-request/blood-glucose-monitoring-devices-market

The global blood glucose monitoring devices market is poised to experience substantial growth over the next five years. One of the primary drivers of this growth is the worldwide increase in the prevalence and incidence of diabetes. The growing number of individuals affected by diabetes has created a significant demand for blood glucose monitoring devices to manage the condition effectively.

Report Scope & Segmentation:

AttributesDetails
Market Size in 2022USD 12.53 Billion
2030 Value ProjectionUSD 23.15 Billion
CAGR8%
Forecast Period2023-2030
Segments Covered
  • Product
  • Testing Site
  • Patient Care Setting
  • Modality
  • Distribution Channel
  • Application
Regions Covered
  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East and Africa

Prominent Players in the Blood Glucose Monitoring Devices Market

  • F. Hoffmann-La Roche Ltd.
  • Sanofi
  • Senseonics
  • Abbott Laboratories
  • Dexcom
  • Medtronic plc
  • LifeScan, Inc. (a subsidiary of Johnson & Johnson)
  • Ascensia Diabetes Care Holdings AG
  • Ypsomed Holding AG
  • Nova Biomedical Corporation
  • ARKRAY Inc.
  • AgaMatrix Holdings LLC
  • Trividia Health Inc.
  • Terumo Corporation
  • Becton, Dickinson and Company
  • Insulet Corporation
  • GlySens Incorporated
  • Echo Therapeutics Inc.
  • Biolinq Inc.
  • Nemaura Medical Inc.

Browse summary of the report and Complete Table of Contents (ToC):

https://www.skyquestt.com/report/blood-glucose-monitoring-devices-market

Self-Monitoring Blood Glucose (SMBG) Devices Segment is Expected to Grow in the Market Due to the Ease of Use and Affordability

The self-monitoring blood glucose (SMBG) devices segment emerged as the largest blood glucose monitoring devices market share holder, accounting for approximately 65% of global revenue share in 2022. This significant market dominance can be attributed to the devices’ ease of use and affordability. SMBG plays a vital role in the everyday management of diabetes, making it an essential component of diabetes care.

The markets in North America emerged as the dominant region in the global blood glucose monitoring devices market, accounting for approximately 35% of the worldwide revenue share in 2022. This market dominance can be attributed to the region’s extensive healthcare industry, which emphasizes the importance of diabetes management and offers advanced medical facilities.

Continuous Glucose Monitoring (CGM) System Segment is Expected to Dominate the Market Due to the Higher Risk of Potentially Life-Threatening Hypoglycemia

The continuous glucose monitoring (CGM) system sector is projected to experience the highest CAGR in the blood glucose monitoring devices market. CGM has emerged as a crucial diabetes treatment tool, particularly for individuals with type 1 diabetes who are at a higher risk of experiencing severe and potentially life-threatening hypoglycemia.

Regional markets in the Asia Pacific are projected to witness the fastest growth in the blood glucose monitoring devices market during the forecast period. This growth can be attributed to several key factors. There has been significant development in healthcare infrastructure across emerging countries in the region.

A comprehensive analysis of the major players in the blood glucose monitoring devices market has been recently conducted in a report. The report encompasses various aspects, including collaborations, mergers, innovative business policies, and strategies, providing valuable insights into key trends and breakthroughs in the market. Furthermore, the report scrutinizes the market share of the top segments and presents a detailed geographic analysis. Lastly, the report highlights the major players in the industry and their endeavours to develop innovative solutions to cater to the growing demand.

Key Developments in the Blood Glucose Monitoring Devices Market

  • Abbott announced in 2022 the development of a groundbreaking bio-wearable that combines a sensor capable of continuously monitoring glucose and ketone levels. This innovative system has been granted the U.S. Food and Drug Administration’s breakthrough device designation. This designation is given to novel technologies that can improve patients’ lives with life-threatening or permanently disabling diseases or disorders.
  • DexCom revealed that its G7 Continuous Glucose Monitoring (CGM) system received the CE Mark in 2022. The G7 CGM system is designed for patients with diabetes aged two years and older, including pregnant women. This certification is a significant milestone for DexCom, as it expands the availability and use of their widely adopted real-time CGM system in Europe.

Speak to Analyst for your custom requirements:

https://www.skyquestt.com/speak-with-analyst/blood-glucose-monitoring-devices-market

Key Questions Answered in Blood Glucose Monitoring Devices Market Report

  • What specific growth drivers are projected to impact the market during the forecast period?
  • List the top companies in the market and explain how they have achieved their positions of influence.
  • In what ways do regional trends and patterns differ within the global market, and how these differences shape the market’s future growth?

Related Reports in SkyQuest’s Library:

Global Osseointegration Implants Market

Global Spinal Fusion Devices Market

Global Nephrostomy Device Market 

Global Ophthalmic Diagnostic Devices Market 

Global Nuclear Imaging Devices Market 

About Us:

SkyQuest Technology is leading growth consulting firm providing market intelligence, commercialization and technology services. It has 450+ happy clients globally.

Address:

1 Apache Way, Westford, Massachusetts 01886

Phone:

USA (+1) 617-230-0741

Email: sales@skyquestt.com

LinkedIn Facebook Twitter

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.